22233-82-5

Usage

Uses

Used in Pharmaceutical Industry:
(E)-1-(2,6-Dihydroxyphenyl)ethanone oxiMe is used as a potential therapeutic agent for its anti-cancer properties. It has demonstrated cytotoxic effects on various cancer cells, making it a promising candidate for the development of new cancer treatments.
Used in Anti-inflammatory Applications:
In the field of anti-inflammatory treatments, (E)-1-(2,6-Dihydroxyphenyl)ethanone oxiMe is used for its potential to alleviate symptoms of rheumatoid arthritis and other inflammatory conditions. Its anti-inflammatory properties make it a valuable compound for further research and development in this area.
Used in Immunosuppressive Applications:
(E)-1-(2,6-Dihydroxyphenyl)ethanone oxiMe is also used as an immunosuppressive agent, which can be beneficial in the treatment of autoimmune diseases. Its ability to modulate the immune system may lead to new therapeutic approaches for conditions where the immune system is overactive or misdirected.

Upstream product

• 699-83-2 2,6-dihydroxylacetophenone 

Downstream Products

• 1380697-19-7 1-(2,6-dihydroxyphenyl)ethanone O-acetyloxime 
• 1380697-20-0 3-methyl-4-[(4-nitrophenyl)oxy]-1,2-benzisoxazole 
• 1380697-21-1 4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]aniline 
• 1380696-11-6 (5R)-5-methyl-3-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-2,4-imidazolidinedione 
• 1380696-13-8 5,5-dimethyl-3-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-2,4-imidazolidinedione 
• 1380697-22-2 1,1-dimethylethyl [(1R)-1-methyl-2-({4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}amino)-2-oxoethyl]carbamate 
• 1380697-23-3 N₁-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-D-alaninamide 
• 1380697-29-9 1,1-dimethylethyl [1,1-dimethyl-2-({4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}amino)-2-oxoethyl]carbamate 
• 1380697-30-2 2-methyl-N₁-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}alaninamide 
• 51110-60-2 2-methylbenzo[d]oxazol-4-ol 
• 51110-58-8 3-Methyl-4-hydroxy-1,2-benzisoxazol 

Relevant academic research and scientific papers

Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102

Although the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-101 has become a standard pharmacological tool compound for in vitro and ex vivo studies in the EAAT research field, its inability to penetrate the blood-brain barrier makes it unsuitable for in vivo studies. In the present study, per os (p.o.) administration (40 mg kg-1) of the closely related analogue UCPH-102 in rats yielded respective plasma and brain concentrations of 10.5 and 6.67 μm after 1 h. Three analogue series were designed and synthesized to improve the bioavailability profile of UCPH-102, but none displayed substantially improved properties in this respect. In vitro profiling of UCPH-102 (10 μm) at 51 central nervous system targets in radioligand binding assays strongly suggests that the compound is completely selective for EAAT1. Finally, in a rodent locomotor model, p.o. administration of UCPH-102 (20 mg kg-1) did not induce acute effects or any visible changes in behavior. EAAT1 inhibition beyond the BBB: In the present study, oral administration (40 mg kg-1) of the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-102 in rats yielded respective plasma and brain concentrations of 10.5 and 6.67 μm after 1 h. In vitro profiling of UCPH-102 (10 μm) at 51 central nervous system targets in radioligand binding assays strongly suggests that the compound is fully selective for EAAT1.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.